NO304638B1 - Peroralt anvendelige legemiddelformer for behandling av sentrale dopaminmangeltilstander - Google Patents

Peroralt anvendelige legemiddelformer for behandling av sentrale dopaminmangeltilstander

Info

Publication number
NO304638B1
NO304638B1 NO932159A NO932522A NO304638B1 NO 304638 B1 NO304638 B1 NO 304638B1 NO 932159 A NO932159 A NO 932159A NO 932522 A NO932522 A NO 932522A NO 304638 B1 NO304638 B1 NO 304638B1
Authority
NO
Norway
Prior art keywords
weight
pct
parts
treatment
dopamine deficiency
Prior art date
Application number
NO932159A
Other languages
English (en)
Norwegian (no)
Other versions
NO932522L (no
NO932522D0 (no
Inventor
Udo Wenzel
G Nther Weber
J Rgen Metzner
Alfred Dorr
Sabine Freitag
Ther Frank-Ulrich Fl
Frank-Michael Albert
Margit Haase
Edith Leistner
Original Assignee
Isis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharma Gmbh filed Critical Isis Pharma Gmbh
Publication of NO932522L publication Critical patent/NO932522L/no
Publication of NO932522D0 publication Critical patent/NO932522D0/no
Publication of NO304638B1 publication Critical patent/NO304638B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO932159A 1991-01-23 1993-07-09 Peroralt anvendelige legemiddelformer for behandling av sentrale dopaminmangeltilstander NO304638B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4101873A DE4101873C2 (de) 1991-01-23 1991-01-23 Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
PCT/DE1992/000043 WO1992012710A1 (de) 1991-01-23 1992-01-23 Peroral applizierbare arzneiform zur behandlung zentraler dopaminmangelzustände

Publications (3)

Publication Number Publication Date
NO932522L NO932522L (no) 1993-07-09
NO932522D0 NO932522D0 (no) 1993-07-09
NO304638B1 true NO304638B1 (no) 1999-01-25

Family

ID=6423528

Family Applications (1)

Application Number Title Priority Date Filing Date
NO932159A NO304638B1 (no) 1991-01-23 1993-07-09 Peroralt anvendelige legemiddelformer for behandling av sentrale dopaminmangeltilstander

Country Status (22)

Country Link
US (1) US5532274A (ja)
EP (1) EP0568577B1 (ja)
JP (1) JP3382940B2 (ja)
AT (1) ATE147264T1 (ja)
AU (1) AU658171B2 (ja)
BG (1) BG61677B1 (ja)
CA (1) CA2101164C (ja)
CZ (1) CZ280847B6 (ja)
DE (2) DE4101873C2 (ja)
DK (1) DK0568577T3 (ja)
EE (1) EE03016B1 (ja)
ES (1) ES2098496T3 (ja)
FI (1) FI101040B (ja)
GR (1) GR3022993T3 (ja)
LT (1) LT3659B (ja)
LV (1) LV11103B (ja)
NO (1) NO304638B1 (ja)
RO (1) RO114737B1 (ja)
RU (1) RU2114619C1 (ja)
SK (1) SK369292A3 (ja)
UA (1) UA27848C2 (ja)
WO (1) WO1992012710A1 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US6531153B2 (en) 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
NZ532568A (en) * 2001-09-28 2005-07-29 Mcneil Ppc Inc Modified release dosage forms
JP2006506362A (ja) * 2002-10-11 2006-02-23 デポメド・ディベロップメント・リミテッド 胃内保持型レボドパデリバリー形態
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
MXPA06002344A (es) 2003-08-29 2006-05-19 Transform Pharmaceuticals Inc Composiciones farmaceuticas y metodo para usar levodopa y carbidopa.
US8815950B2 (en) * 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
JP2008534563A (ja) * 2005-03-28 2008-08-28 オレクソ・アクチエボラゲット パーキンソン病の治療に有用な新しい製薬組成物
CA2613631A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
US20070275060A1 (en) * 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
US20100316712A1 (en) * 2006-12-22 2010-12-16 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2009085306A1 (en) 2007-12-28 2009-07-09 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
EP2233131A1 (en) * 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
KR20130009553A (ko) * 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
KR102266091B1 (ko) 2013-10-07 2021-06-17 임팩스 라보라토리즈, 인코포레이티드 레보도파 및/또는 레보도파의 에스테르의 점막-점착성, 제어 방출형 제제 그리고 이의 용도
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
JP6695013B1 (ja) * 2018-11-13 2020-05-20 日本酢ビ・ポバール株式会社 結合剤
CN112955136A (zh) * 2018-11-13 2021-06-11 日本瓦姆&珀巴尔株式会社 粘结剂
JP6694564B1 (ja) * 2018-11-13 2020-05-13 日本酢ビ・ポバール株式会社 結合剤
CN112969455A (zh) * 2018-11-13 2021-06-15 日本瓦姆&珀巴尔株式会社 粘结剂
WO2021205886A1 (ja) * 2020-04-10 2021-10-14 日本酢ビ・ポバール株式会社 結合剤
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE631201C (de) * 1932-08-07 1936-06-16 Chemische Forschungs Gmbh Traegerstoff fuer Arzneimittel
DE748317C (de) * 1941-08-17 1944-12-19 Wacker Chemie Gmbh Verfahren zur Herstellung in Wasser zerfallender Faeden, Filme, Baender, Schlaeuche u. dgl. aus unvollstaendig verseiften Polyvinylalkoholen
US3584113A (en) * 1967-08-31 1971-06-08 Eisai Co Ltd Process for the production of medical preparations having sustained release of therapeutical effect
NL149372B (nl) * 1968-10-01 1976-05-17 Merck & Co Inc Werkwijze voor het bereiden van farmaceutische preparaten, alsmede de door toepassing daarvan verkregen gevormde voortbrengselen.
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
IE49522B1 (en) 1979-04-26 1985-10-16 Merrell Toraude & Co Alpha-halomethylaminoacids
DE3042916A1 (de) * 1979-06-01 1982-07-01 Joachim 7440 Nürtingen Dudzik Tablette
CA1218604A (en) * 1981-07-08 1987-03-03 Alec D. Keith Trinitroglycerol sustained release vehicles and preparations therefrom
CH652025A5 (de) 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
EP0147780A3 (en) * 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
US4927633A (en) * 1984-03-19 1990-05-22 Alza Corporation Dispenser for delivering drug to livestock
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US4892778A (en) * 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4940465A (en) * 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
CA1331563C (en) * 1987-08-03 1994-08-23 Gaylen M. Zentner Device for the controlled release of drugs with donnan-like modulation by charged insoluble resins
AU608891B2 (en) * 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
ES2052681T5 (es) * 1987-12-31 1997-12-01 Asta Medica Ag Combinacion sinergica de inhibidores de descarboxilasa y granulos de l-dopa.
DE3841955A1 (de) * 1987-12-31 1989-07-13 Asta Pharma Ag Synergistische kombination von decarboxylasehemmern und l-dopa-pellets

Also Published As

Publication number Publication date
CZ369292A3 (en) 1993-09-15
EP0568577A1 (de) 1993-11-10
ES2098496T3 (es) 1997-05-01
DE4101873A1 (de) 1992-07-30
DK0568577T3 (da) 1997-06-30
SK278736B6 (sk) 1998-02-04
AU1186892A (en) 1992-08-27
LTIP555A (en) 1994-11-25
RU2114619C1 (ru) 1998-07-10
DE59207852D1 (de) 1997-02-20
UA27848C2 (uk) 2000-10-16
GR3022993T3 (en) 1997-07-30
ATE147264T1 (de) 1997-01-15
DE4101873C2 (de) 1993-12-09
LV11103B (en) 1996-06-20
CA2101164A1 (fr) 1992-07-24
US5532274A (en) 1996-07-02
JPH06504543A (ja) 1994-05-26
EP0568577B1 (de) 1997-01-08
LT3659B (en) 1996-01-25
CZ280847B6 (cs) 1996-04-17
WO1992012710A1 (de) 1992-08-06
BG61677B1 (bg) 1998-03-31
RO114737B1 (ro) 1999-07-30
AU658171B2 (en) 1995-04-06
JP3382940B2 (ja) 2003-03-04
BG97894A (bg) 1994-04-29
FI101040B (fi) 1998-04-15
LV11103A (lv) 1996-04-20
SK369292A3 (en) 1998-02-04
NO932522L (no) 1993-07-09
EE03016B1 (et) 1997-08-15
FI933304A0 (fi) 1993-07-22
NO932522D0 (no) 1993-07-09
FI933304A (fi) 1993-07-22
CA2101164C (fr) 2001-04-24

Similar Documents

Publication Publication Date Title
NO304638B1 (no) Peroralt anvendelige legemiddelformer for behandling av sentrale dopaminmangeltilstander
KR960700054A (ko) 파킨슨씨 병 및 파킨슨 증후군의 치료에 리루졸의 이용(application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes)
IL117356A0 (en) Controlled release pharmaceutical composition for oral administration
KR880000098A (ko) 콘드로이틴 설페이트 면역자극 조성물
TW273550B (ja)
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
SE9503143D0 (sv) New preparation
RU93051537A (ru) Перорально вводимая лекарственная форма
CA2136404A1 (fr) Composition solide mucoadhesive, therapeutique ou hygienique, pour administration par application sur la muqueuse buccale ou nasale
ATE315399T1 (de) Hemmung von systemischen infektionen in menschen und wirbeltieren mit ballaststoffen
FI955837A (fi) Menetelmä suun kautta annettavan, kiinteän, diklofenaakkia sisältävän annostelumuodon valmistamiseksi
US5082665A (en) Anti-snoring formulations using yohimbine
KR920021144A (ko) 역류성 식도염을 치료하기위한 니자티딘의 용도
ES2139774T3 (es) Uso de una combinacion de antineoplastones en la preparacion de un medicamento para el tratamiento de la neurofibromatosis.
Farina et al. Antibacterial activity of Nicaraguan vegetal extracts used in folk medicine
KR960700053A (ko) 방사선회복제로서 리루졸의 이용(application of riluzole as a radiorestorer)
KR960033451A (ko) 나트륨 치환 트립토판을 포함하는 b형 간염 치료제
KR960021046A (ko) 카페익산을 포함하는 b형 간염 치료제
JPS57105423A (en) Chloroethylureidopropylpolysilsesquioxane
UA27711C2 (uk) Фармацевтична композиція для лікування патологічних станів, пов'язаних з активністю лейкотриєнів
KR890002058A (ko) 간질 및 불안 상태의 예방 및 치료용 2,4,6-트리스-3-급-부틸아미노-1,-3,-5-트리아진

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees